Personalised Immunotherapy in Sepsis:
a precision medicine approach

Approach

Over the duration of the project, ImmunoSep achieved four key aims:

aims

Aim 1: Provide proof that a personalised immunotherapy approach is feasible for the treatment of sepsis

ImmunoSep conducted the first large-scale personalised immunotherapy trial in sepsis, establishing proof-of-principle and assessing the clinical value of already available immunotherapeutic agents.

Aim 2: Build the basis on which improvements can be made for the future second-generation studies

Through systems biology and multi-layered omics immunoprofiling—using cutting-edge technologies including single-cell sequencing, genomics, epigenomics, metabolomics, and microbiome analysis—the project achieved its aim to improve patient stratification and treatment allocation.

Aim 3: Design new theranostics pipelines

Using the database generated from the multi-omics assessment of sepsis patients, ImmunoSep achieved its aim to lay the the groundwork for designing and executing future precision medicine-based immunotherapy trials in sepsis.

Aim 4: Integration of novel immunotherapeutic approaches daily healthcare

By collaborating with professionals and patient organisations, ImmunoSep promoted patient awareness and involvement in these decision processes, and enhanced the acceptability of immunotherapies as a new treatment in sepsis.